Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma
- 100 Downloads
The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.
KeywordsDiffuse large B cell lymphoma Survival TGFβRII
Compliance with Ethical Standards
Conflicts of interest
The study protocol was approved by the Ethics Committee of Liaoning Medical University, and written informed consent was obtained from all participants involved in the study.
Shudan Mao and Wenqi Yang conducted the experiments and drafted the manuscript. Zhe Li and Limei Ai participated in the design of the study and performed the statistical analysis. Jieping Jin conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
- 1.Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues (edition 4). Lyon: International Agency for Research on Cancer Press; 2008.Google Scholar
- 5.Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.CrossRefPubMedGoogle Scholar
- 16.Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. 2013 Aug 27. pii: S0960-7404(13)00066-2.Google Scholar